Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Background: Liver fibrosis (LF) is a common pathological process characterized by the activation of hepatic stellate cells (HSCs) and accumulation of extracellular matrix. Severe LF causes cirrhosis and even liver failure, a major cause of morbidity and mortality worldwide. Transplantation of human placental mesenchymal stem cells (hPMSCs) has been considered as an alternative therapy. However, the underlying mechanisms and the appropriate time window for hPMSC transplantation are not well understood. Methods: We established mouse models of CCl 4-injured LF and administered hPMSCs at different stages of LF once a week for 2 weeks. The therapeutic effect of hPMSCs on LF was investigated, according to histopathological and blood biochemical analyses. In vitro, the effect of hPMSCs and the secretomes of hPMSCs on the inhibition of activated HSCs was assessed. RNA sequencing (RNA-seq) analysis, real-time PCR array, and western blot were performed to explore possible signaling pathways involved in treatment of LF with hPMSCs. Results: hPMSC treatment notably alleviates experimental hepatic fibrosis, restores liver function, and inhibits inflammation. Furthermore, the therapeutic effect of hPMSCs against mild-to-moderate LF was significantly greater than against severe LF. In vitro, we observed that the hPMSCs as well as the secretomes of hPMSCs were able to decrease the activation of HSCs. Mechanistic dissection studies showed that hPMSC treatment downregulated the expression of fibrosis-related genes, and this was accompanied by the upregulation of Caveolin-1 (Cav1) (p < 0.001). This suggested that the amelioration of LF occurred partly due to the restoration of Cav1 expression in activated HSCs. Upregulation of Cav1 can inhibit the TGF-β/Smad signaling pathway, mainly by reducing Smad2 phosphorylation, resulting in the inhibition of activated HSCs, whereas this effect could be abated if Cav1 was silenced in advance by siRNAs. Conclusions: Our findings suggest that hPMSCs could provide multifaceted therapeutic benefits for the treatment of LF, and the TGF-β/Cav1 pathway might act as a therapeutic target for hPMSCs in the treatment of LF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cell perspective: cell biology to clinical progress
Pittenger, M. F., Discher, D. E., Péault, B. M., Phinney, D. G., Hare, J. M., & Caplan, A. I. (2019) · npj Regenerative Medicine · doi:10.1038/s41536-019-0083-6 · Cited by 2,008
Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine
Vizoso, F., Eiro, N., Cid, S., Schneider, J., & Perez-Fernandez, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091852 · Cited by 1,363 · cited 1×
“Recent studies now support that the beneficial effects observed with MSC-based therapy can be mediated through the paracrine release of soluble proteins or other biologically active molecules and extracellular vesicles, which together constitute the MSC secretomes [6, 16, 25, 28, 29].”
BackgroundTGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695 · cited 2×
“Interestingly, the proportion of Kupffer cells (CD11bF4/80) [27] was 17.”
BackgroundStem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders
Riazifar, M., Mohammadi, M. R., Pone, E. J., Yeri, A., Lässer, C., Segaliny, A. I., McIntyre, L. L., Shelke, G. V., Hutchins, E., Hamamoto, A., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b01004 · Cited by 551
HEO, J. S., CHOI, Y., KIM, H.-S., & KIM, H. O. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2413 · Cited by 495
Mesenchymal stem cell therapy for liver fibrosis
Eom, Y. W., Shim, K. Y., & Baik, S. K. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.5.580 · Cited by 226 · cited 1×
“In summary, the following mechanisms may account for them: Transplanted hPMSCs inhibit the secretion of multiple cytokines that otherwise promote inflammation and impair liver restoration [6, 15, 33].”
BackgroundMesenchymal stem cell therapy for liver fibrosis/cirrhosis
Cao, Y., Ji, C., & Lu, L. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.119 · Cited by 99 · cited 2×
“Recently, many studies have demonstrated the therapeutic potential of mesenchymal stem cells (MSCs) in liver disease [9, 10].”
BackgroundLuo, X.-Y., Meng, X.-J., Cao, D.-C., Wang, W., Zhou, K., Li, L., Guo, M., & Wang, P. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1122-8 · Cited by 99 · cited 1×
“In summary, the following mechanisms may account for them: (1) Transplanted hPMSCs inhibit the secretion of multiple cytokines that otherwise promote in ammation and impair liver restoration (6, 17, 32).”
Background
Cited by
Stem cells for treatment of liver fibrosis/cirrhosis: clinical progress and therapeutic potential
Liu, P., Mao, Y., Xie, Y., Wei, J., & Yao, J. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03041-5 · Cited by 82
Zhu, D., Sun, Z., Wei, J., Zhang, Y., An, W., Lin, Y., & Li, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s450284 · Cited by 17
Cell therapy for end-stage liver disease: Current state and clinical challenge
Zhang, L., Deng, Y., Bai, X., Wei, X., Ren, Y., Chen, S., & Deng, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003332 · Cited by 12
“…that MSC treatment ameliorates liver fibrosis by upregulating the expression of Caveolin1 and inhibiting the TGF-β /Smad signaling pathway in HSCs. [91] Apart from the TGF-β pathway, Qiao et al [92] proved that MSCs significantly inhibited the proliferation of activated HSCs by inhibiting the…”
Self-citationSlautin, V., Konyshev, K., Gavrilov, I., Beresneva, O., Maklakova, I., & Grebnev, D. (2024) · Current Stem Cell Research & Therapy · doi:10.2174/011574888x279940231206100902 · Cited by 7
Metadata
- Authors
- Yao, Y., Xia, Z., Cheng, F., Jang, Q., He, J., Pan, C., Zhang, L., Ye, Y., Wang, Y., Chen, S., Su, D., Su, X., Cheng, L., Shi, G., Dai, L., & Deng, H.
- Venue
- Stem Cell Research & Therapy
- Published
- 2021-05-20
- Volume
- 12
- Issue
- 1
- Pages
- 294-294
- ISSN
- 1757-6512 (ISSN-L)
- OpenAlex
- W3158672151
- Cited by
- 20
- References
- 9
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells. https://app.cochat.ai/papers/10.1186/s13287-021-02358-x
- The paper
- Yao, Y., Xia, Z., Cheng, F., Jang, Q., He, J., Pan, C., Zhang, L., Ye, Y., Wang, Y., Chen, S., Su, D., Su, X., Cheng, L., Shi, G., Dai, L., & Deng, H. (2021). Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-021-02358-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.